The E3 Ubiquitin Ligase TRIM40 Attenuates Antiviral Immune Responses by Targeting MDA5 and RIG-I

Area of Science:

• Immunology
• Molecular Biology
• Virology

Background:

• Retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), including MDA5 and RIG-I, are critical for detecting viral RNA and initiating innate immune responses.
• Tight regulation of RLR expression and activation is essential for maintaining immune homeostasis and effectively combating viral infections.
• The precise mechanisms controlling RLR expression remain incompletely understood.

Purpose of the Study:

• To identify novel regulators of RLR signaling.
• To investigate the role of tripartite interaction motif 40 (TRIM40) in modulating RLR-mediated innate immunity.
• To elucidate the molecular mechanisms by which TRIM40 affects MDA5 and RIG-I.

Main Methods:

• Identification of TRIM40 as an MHC-encoded gene.
• Biochemical assays to demonstrate TRIM40 binding to MDA5 and RIG-I.
• Assessment of TRIM40's E3 ligase activity and its role in polyubiquitination.
• Analysis of proteasomal degradation pathways.
• In vivo studies evaluating TRIM40 deficiency in antiviral responses and viral replication.

Main Results:

• TRIM40 directly targets MDA5 and RIG-I for degradation.
• TRIM40 promotes K27- and K48-linked polyubiquitination of MDA5 and RIG-I, leading to proteasomal degradation.
• TRIM40 deficiency results in enhanced RLR-triggered signaling.
• TRIM40-deficient mice exhibit heightened antiviral immune responses and reduced viral loads in vivo.

Conclusions:

• TRIM40 acts as a negative regulator of RLR-mediated innate immune activation.
• TRIM40 limits antiviral responses by promoting the degradation of key RLRs, MDA5 and RIG-I.
• TRIM40 represents a potential therapeutic target for enhancing antiviral immunity and controlling viral infections.